Review Article

The Modified Atkins Diet in Refractory Epilepsy

Suvasini Sharma and Puneet Jain

Division of Pediatric Neurology, Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children’s Hospital, New Delhi 110001, India

Correspondence should be addressed to Suvasini Sharma; sharma.suvasini@gmail.com

Received 23 October 2013; Accepted 10 December 2013; Published 30 January 2014

Academic Editor: József Janszky

Copyright © 2014 S. Sharma and P. Jain. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The modified Atkins diet is a less restrictive variation of the ketogenic diet. This diet is started on an outpatient basis without a fast, allows unlimited protein and fat, and does not restrict calories or fluids. Recent studies have shown good efficacy and tolerability of this diet in refractory epilepsy. In this review, we discuss the use of the modified Atkins diet in refractory epilepsy.

1. Introduction

Seizures are a frequent cause of morbidity in the pediatric age group [1]. Several severe catastrophic epilepsies present in childhood, including severe infantile myoclonic epilepsy, West syndrome, Lennox-Gastaut syndrome, and myoclonic-astatic epilepsy (Doose syndrome) [2]. Seizures in these epilepsy syndromes are difficult to control, with the added problems of multiple and toxic levels of antiepileptic medications [3]. Epilepsy surgery may not work in these patients and also the costs are prohibitively high. Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment [4]. The shortcomings of antiepileptic drug therapy and epilepsy surgery have made the need for alternative treatments.

The traditional ketogenic diet, with 4:1 ratio of fat:carbohydrate + protein, has its drawbacks. It restricts calories and fluids and requires strict weighing of foods. Protein is generally restricted, with the majority of the remaining calories in the form of fat. This may lead to hypoproteinemia and growth problems. Hospitalization is generally advocated for diet initiation. Side effects of the diet include kidney stones, constipation, acidosis, diminished growth, weight loss, and hyperlipidemia [7–11].

The modified Atkins diet is a less restrictive alternative to the traditional ketogenic diet [12, 13]. This diet is started on an outpatient basis without a fast, allows unlimited protein and fat, and does not restrict calories or fluids [12–14]. In this review we discuss the use of the modified Atkins diet in refractory epilepsy.

2. The Atkins Diet

The Atkins diet was developed in the United States in 1970 by Robert C. Atkins for the purpose of weight loss. This diet allowed the intake of fat and the restriction of carbohydrates. The modified Atkins diet is “modified” from the Atkins diet as the “induction phase” of the diet limiting carbohydrates is maintained indefinitely, fat is encouraged (not just allowed), and seizure control is the goal rather than weight loss [15]. In contrast to the ketogenic diet, it does not restrict protein intake or daily calories. The Atkins diet allows meals containing 60% fat, 30% protein, and 10% carbohydrates [16].
With its comparatively fewer dietary restrictions, the Atkins diet may be less restrictive than the ketogenic diet. Kossoff et al. hypothesized that the Atkins diet can induce metabolic ketosis and might reduce seizures in patients with epilepsy, similar to the ketogenic diet [12]. In 2003, they published a pilot study of six patients, aged 7 to 52 years, who were started on the Atkins diet for the treatment of intractable focal and multifocal epilepsy [12]. Five patients maintained moderate to large ketosis for periods of 6 weeks to 24 months; three patients had seizure reduction and were able to reduce antiepileptic medications. This study provided preliminary evidence that the Atkins diet may have a role as therapy for patients with medically resistant epilepsy.

The same group published their experience with the modified Atkins diet in 20 children with intractable epilepsy in 2006 [13]. Eighty percent of the patients stayed on the diet for six months. In all children, at least moderate urinary ketosis developed within 4 days of starting the modified Atkins diet. At 6 months on the diet, 65% had a >50% response, and 35% had a >90% response. This was strikingly similar to prospective studies on the traditional ketogenic diet [8].

Kang et al. evaluated the efficacy, safety, and tolerability of the modified Atkins diet in fourteen Korean children with refractory epilepsy [14]. Six months after diet initiation, seven (50%) remained on the diet, five (36%) had >50% seizure reduction, and three (21%) were seizure free. The diet was well tolerated by 12 (86%) patients, despite the fact that this was a predominantly rice eating population.

The ideal starting carbohydrate limit in the modified Atkins diet is not yet established. Preliminary studies used 10 grams of carbohydrates/day. However, in one of these studies, 10 (50%) of 20 children had increased carbohydrates to 15 g per day after the first month, and one child increased to 20 g per day after the fourth month, as assessed by the dietary chart reviews [13]. Only one of these children reported a reduction in efficacy as a result, and none described decreased levels of urinary ketosis. Based on these results, Kossoff et al. performed a study to determine the initiating carbohydrate limits in the modified Atkins diet [18]. Twenty children with intractable epilepsy were randomized to either 10 or 20 g of carbohydrates per day for the initial 3 months of the modified Atkins diet and then crossed over to the opposite amount. A significantly higher likelihood of >50% seizure reduction was noted for children started on 10 g of carbohydrate per day at 3 months: 60% versus 10% (P = 0.03). Most parents reported no change in seizure frequency or ketosis between groups but improved tolerability with 20 g per day. The authors concluded that a starting carbohydrate limit of 10 g per day for children starting the modified Atkins diet may be ideal, with a planned increase to a more tolerable 20 g per day after 3 months. Table 1 summarizes the pediatric studies of MAD.

In a recent randomized controlled trial [28], 102 children aged 2 to 14 years who had daily seizures despite the appropriate use of at least 3 antiepileptic drugs were randomized to receive either the modified Atkins diet (n = 50) or no dietary intervention (n = 52) for a period of three months. The ongoing antiepileptic medications were continued unchanged in both groups. Four patients discontinued the diet before the study endpoint, and three patients in the control group were lost to follow up. The median seizure frequency at 3 months, expressed as a percentage of the baseline, was significantly less in the diet group (37.3% versus 100%, P = 0.003). The proportion of children with >90% seizure reduction (30% versus 7.7%, P = 0.005) and >50% seizure reduction was significantly higher in the diet group (52% versus 11.5%, P < 0.001). Constipation was the commonest adverse effect (46%) among children on the diet.

Most of the studies have reported short term seizure outcome following diet initiation. Recently, Chen and Kossoff [34] reported long term follow-up of 87 MAD-treated children. Fifty-four children continued diet beyond 6 months. After a mean of 19.9 months on diet, 30/54 (55%) children with diet durations of >6 months achieved >50% improvement and 19 (35%) were seizure-free. The adverse effects were predominantly elevations in lipid profile and gastrointestinal upset.

This diet has the advantages of nonfasting initiation. Also, it can be used in resource constraint settings with limited dietician support, as it does not require tedious calculations [35]. The counseling time is reduced to 30–60 minutes. In the West, this diet has predominantly been advocated for adolescents and adults. However, in India, this diet has been found useful in young children as well. In a study of 15 children, aged 6 months to 3 years, with infantile spasms refractory to hormonal therapy and/or vigabatrin, the modified Atkins diet was found to render 6 children (40%) spasm free with EEG resolution of hypsarrhythmia at 3 months [26]. The diet was well tolerated in these young children.

Further, the efficacy of the ketogenic diet can be maintained when switching to MAD [12]. The information
Table 1: Summary of studies involving children treated with MAD.

| Authors                        | Study type                                      | Sample size | Age range   | Epilepsy                                                                 | At 3 months | Adverse effects                              |
|--------------------------------|------------------------------------------------|-------------|-------------|---------------------------------------------------------------------------|-------------|-----------------------------------------------|
| Kossoff et al. 2003 [12]       | Open trial                                     | 6           | 7–52 yrs    | Mixed                                                                     | 3           | —                                             |
| Kossoff et al. 2006 [13]       | Prospective                                    | 20          | 3–18 yrs    | ≥3 Sz/week on at least 2 AEDs                                            | 50%         | 11%                                           |
| Kossoff et al. 2007 [18]       | Randomized cross-over (10 g versus 20 g)       | 20          | 3–18 yrs    | At least daily countable seizures                                         | 10 g—60%    | 10 g—30% 20 g—0%                             |
| Kang et al. 2007 [14]          | Prospective                                    | 14          | Mean 7.4 yrs | ≥4 Sz/month; ≥3 AEDs                                                     | 50%         | 29%                                           |
| Porta et al. 2009 [19]         | Retrospective                                  | 27          | 4–182 months| ≥2 Sz/week, ≥3 AEDs                                                      | KD—64%      | —                                             |
| Weber et al. 2009 [20]         | Prospective                                    | 15          | 2–17 yrs    | ≥1 Sz/week, ≥2 AEDs                                                      | 40%         | 13%                                           |
| Tonekaboni et al. 2010 [21]    | Prospective                                    | 27          | 1–16 yrs    | ≥3 AEDs tried                                                             | 67%         | 25%                                           |
| Miranda et al. 2010 [22]       | Prospective                                    | 33          | 1–16 yrs    | Medically intractable epilepsy                                           | 52%         | 42%                                           |
| Kossoff et al. 2011 [23]       | Prospective (MAD + 1 month Ketocal)            | 30          | 3–18 yrs    | At least daily countable seizures; ≥2 AEDs                                | At 1 month, | 37%                                           |
| Groomes, et al. 2011 [24]      | Retrospective + prospective (8-ketogenic diet, 13-MAD) | 21          | Median age at diet onset—6 yrs | Intractable childhood and juvenile absence epilepsy | At 2 months, 70% | Constipation                              |
| Kumada et al. 2012 [25]        | Prospective                                    | 10          | 1.5–17 yrs  | ≥3 Sz/week, ≥3 AEDs                                                      | At 3 weeks, 3 | 2                                              |
| Sharma et al. 2012 [26]        | Prospective                                    | 15          | 6 m–3 yrs   | Daily infantile spasms                                                   | 40% spasm free | Constipation                              |
| Kim et al. 2012 [27]           | Retrospective                                  | 20          | 21 m–17 yrs | Mixed                                                                     | 55%*        | 35%*                                          |
| Sharma et al. 2013 [28]        | Randomized controlled trial                    | Total 102, 50 randomized to diet group | 2–14 yrs | Daily seizures, or at least 7/week                                       | 52% in diet group versus 11.5% in control group | Constipation, anorexia, vomiting, lethargy |

* Efficacy during the recent or final 3 months of the diet therapy.

AEDs: antiepileptic drugs; Sz: seizures; MAD: modified Atkins diet; KD: ketogenic diet.

regarding additional seizure control when switching from MAD to ketogenic diet is limited. In one retrospective review, 37% of patients (10/27) had ≥10% additional seizure reduction with the KD over the MAD with most favorable response seen in children with myoclonic ataxic epilepsy [36].

4. MAD in Adults

Three open-label studies have reported use of the MAD exclusively in adults [30, 31, 33]. Three studies have reported on adolescents in mixed cohorts of children and adolescents [14, 20, 32]. One case series has included one adolescent and three adults [12]. Data from six studies show that, on average, 18 of 66 (27%) adolescents and adults achieved ≥50% seizure reduction; of these 66 individuals, 1 (6%) became seizure-free. Treatment may be slightly more effective in those with higher initial seizure frequencies and in younger adults.

One study found that, after an average of 3 days, all adults had positive results for urinary ketones, both in the morning and evening [31]. In another study, all 28 adults
Table 2: A summary of studies that include data specifically on individuals aged >12 years on MAD [29].

| Study                  | Study design | Sample size (adolescents/adults) | Age (yrs) | Seizure types                      | Endpoint (mths) | Number of adolescent (12–18yrs) responders (%) (>50% reduction) | Number of adult (>18yrs) responders at endpoint (%) (>50% reduction) | Adverse effects                                                                 |
|------------------------|--------------|----------------------------------|-----------|------------------------------------|-----------------|------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Kang et al. 2007 [14]  | Prospective  | 1 (1/0)                          | 14.4      | DS with ATS                        | 7               | 0 (0%)                                                          | NA                                                                  | Vomiting                                                                   |
| Kossoff et al. 2008 [30]| Prospective  | 30 (0/30)                        | 18–53     | CPS, MST, AS                       | 6               | NA                                                              | 9 (30%)                                                            | Lethargy, weight loss, elevated total cholesterol, leg swelling |
| Carrette et al. 2008 [31]| Prospective  | 8 (0/8)                          | 31–55     | CPS, CPS with occasional SG, LGS   | 6               | NA                                                              | 1 (13%)                                                            | Vomiting, headache, nausea, diarrhoea, constipation, weakness, weight loss, elevated total and LDL cholesterol |
| Weber et al. 2009 [20]| Prospective  | 7 (7/0)                          | 12–17     | SFE, LGS, MAE, JME                 | 3               | 3 (43%)                                                        | NA                                                                  | Unknown                                                                   |
| Kossoff et al. 2010 [32]| Prospective  | 2 (2/0)                          | 13–18     | SWS with CPS                       | 6               | 1 (50%)                                                        | NA                                                                  | Weight loss, high peak total cholesterol                               |
| Smith et al. 2011 [33]| Prospective  | 18 (0/18)                        | 18–55     | PS with SG, MS, CPS, SPS           | 12              | NA                                                              | 3 (17%)                                                            | Weight loss                                                                |

AS: absence seizures; ATS: atonic seizures; CPS: complex partial seizures; DS: Doose syndrome; JME: juvenile myoclonic epilepsy; LGS: Lennox-Gastaut syndrome; MAE: myoclonic astatic epilepsy; MS: myoclonic seizures; MST: multiple seizure types; NA: not available; PS: partial seizures; SFE: symptomatic focal epilepsy; SG: secondary generalization; SPS: simple partial seizures; SWS: Sturge-Weber syndrome.
who remained on the diet for at least 1 week became ketogenic, but only 2 of 15 (13%) had moderate-large urinary ketosis after 6 months [30]. Ketone levels do not always correlate with improved efficacy in adults [30, 33] or in mixed cohorts of children and adolescents [13, 23, 32]. Table 2 summarizes the studies of MAD in adults.

5. Other Uses of MAD

The MAD has rarely been used for other indications. Its successful use has been reported in Sturge-Weber syndrome [32] and GLUT1 deficiency syndrome [37]. Kumada et al. [38] reported resolution of nonconvulsive status epilepticus following administration of MAD to two children, one with frontal lobe epilepsy and the other with subcortical band heterotopias. Kossoff et al. reported use of MAD in adolescents with chronic daily headache. Only 3 patients out of 8 completed the three-month study. Two of them reported improvement in their headache severity [39].

6. Tolerability and Side Effects

The modified Atkins diet has generally been well tolerated. In the study by Kossoff et al., significant constipation was reported in four children [13]. Six children lost weight, median of 2.7 kg, three of whom were the heaviest in the cohort. Cholesterol values increased from a mean of 192 mg/dL to 221 mg/dL at the end of 6 months, but this increase was half of the reported increase with the ketogenic diet [40]. In the study on 30 adults who were administered the modified Atkins diet for refractory epilepsy, total cholesterol increased from 187 mg/dL to 201 mg/dL, but the LDL, HDL, and triglycerides remained in average risk ranges [30].

Gastrointestinal side effects such as constipation and vomiting have been the commonest side effects reported [12–14, 18, 30, 31]. These are most marked at the initiation of the diet, with time they improve [31]. Weight loss is prominent in obese patients [30]. One child developed aspiration pneumonia in the study by Kang et al. [14]. Kidney stones, seen in 5% of patients on the ketogenic diet, have not been reported with the modified Atkins diet to date.

7. Conclusion

MAD is an efficacious therapy for patients with refractory epilepsy. It is less restrictive and more palatable than the classical ketogenic diet. There is limited data regarding the efficacy of MAD with respect to the classical ketogenic diet. However, MAD is a prudent therapeutic option especially for older children and adolescents as it is a more "liberalized" diet as compared to classical ketogenic diet. It is also a good option for resource-constraint settings with paucity of trained dieters.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] W. A. Hauser, “The prevalence and incidence of convulsive disorders in children,” Epilepsia, vol. 35, supplement 2, pp. S1–S6, 1994.
[2] J. M. Pellock, “Seizures and epilepsy in infancy and childhood,” Neurologic Clinics, vol. 11, no. 4, pp. 755–775, 1993.
[3] P. N. Patsalos and J. S. Duncan, “Antiepileptic drugs. A review of clinically significant drug interactions,” Drug Safety, vol. 9, no. 3, pp. 156–184, 1993.
[4] S. Shorvon, F. Dreifuss, and D. Fish, The Treatment of Epilepsy, Blackwell Science, 1996.
[5] F. J. Ritter, I. E. Leppik, F. E. Dreifuss et al., “Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome),” The New England Journal of Medicine, vol. 328, no. 1, pp. 29–33, 1993.
[6] R. George, M. Salinsky, R. Kuzniecky et al., “Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study,” Epilepsia, vol. 35, no. 3, pp. 637–643, 1994.
[7] E. P. G. Vining, J. M. Freeman, K. Ballaban-Gil et al., “A multicenter study of the efficacy of the ketogenic diet,” Archives of Neurology, vol. 55, no. 11, pp. 1433–1437, 1998.
[8] J. M. Freeman, E. P. G. Vining, D. J. Pillas, P. L. Pyzik, J. C. Casey, and M. T. Kelly, “The efficacy of the ketogenic diet—1998: a prospective evaluation of intervention in 150 children,” Pediatrics, vol. 102, no. 6, pp. 1358–1363, 1998.
[9] A. M. Hassan, D. L. Keene, S. E. Whiting, P. J. Jacob, J. R. Champagne, and P. Humphreys, “Ketogenic diet in the treatment of refractory epilepsy in childhood,” Pediatric Neurology, vol. 21, no. 2, pp. 548–552, 1999.
[10] N. G. Katyal, A. N. Koehler, B. McGhee, C. M. Foley, and P. K. Crumrine, “The ketogenic diet in refractory epilepsy: the experience of Children's Hospital of Pittsburgh,” Clinical Pediatrics, vol. 39, no. 3, pp. 153–159, 2000.
[11] P. Kankirawatana, P. Jirapinyo, S. Kankirawatana, R. Wongarn, and N. Thamanasiri, “Ketogenic diet: an alternative treatment for refractory epilepsy in children,” Journal of the Medical Association of Thailand, vol. 84, no. 7, pp. 1027–1032, 2001.
[12] E. H. Kossoff, G. L. Krauss, J. R. McCrogan, and J. M. Freeman, “Efficacy of the Atkins diet as therapy for intractable epilepsy,” Neurology, vol. 61, no. 12, pp. 1789–1791, 2003.
[13] E. H. Kossoff, J. R. McCrogan, R. M. Bluml, D. J. Pillas, J. E. Rubenstein, and E. P. Vining, “A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy,” Epilepsia, vol. 47, no. 2, pp. 421–424, 2006.
[14] H.-C. Kang, H. S. Lee, S. J. You, D. C. Kang, T.-S. Ko, and H. D. Kim, “Use of a modified Atkins diet in intractable childhood epilepsy,” Epilepsia, vol. 48, no. 1, pp. 182–186, 2007.
[15] E. H. Kossoff and J. L. Dorward, “The modified Atkins diet,” Epilepsia, vol. 49, supplement 8, pp. 37–41, 2008.
[16] E. H. Kossoff, “More fat and fewer seizures: dietary therapies for epilepsy,” The Lancet Neurology, vol. 3, no. 7, pp. 415–420, 2004.
[17] R. Atkins, Dr. Atkins' New Diet Revolution, Harper-Collins Publishers, 2004.
[18] E. H. Kossoff, Z. Turner, R. M. Bluml, P. L. Pyzik, and E. P. G. Vining, “A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet,” Epilepsy and Behavior, vol. 10, no. 3, pp. 432–436, 2007.
[19] N. Porta, L. Vallée, E. Boutry et al., “Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet,” *Seizure*, vol. 18, no. 5, pp. 359–364, 2009.

[20] S. Weber, C. Mølgaard, K. Karen Taudorf, and P. Uldall, “Modified Atkins diet to children and adolescents with medical intractable epilepsy,” *Seizure*, vol. 18, no. 4, pp. 237–240, 2009.

[21] S. H. Tonekaboni, P. Mostaghimi, P. Mirmiran et al., “Efficacy of the Atkins diet as therapy for intractable epilepsy in children,” *Archives of Iranian Medicine*, vol. 13, no. 6, pp. 492–497, 2010.

[22] M. J. Miranda, M. Mortensen, J. H. Povlsen, H. Nielsen, and S. Beniczky, “Danish study of a modified Atkins diet for medically intractable epilepsy in children: can we achieve the same results as with the classical ketogenic diet?” *Seizure*, vol. 20, no. 2, pp. 151–155, 2011.

[23] E. H. Kossoff, J. L. Dorward, Z. Turner, and P. L. Pyzik, “Prospective study of the modified Atkins diet in combination with a ketogenic liquid supplement during the initial month,” *Journal of Child Neurology*, vol. 26, no. 2, pp. 147–151, 2011.

[24] L. B. Groomes, P. L. Pyzik, Z. Turner, J. L. Dorward, V. H. Goode, and E. H. Kossoff, “Do patients with absence epilepsy respond to ketogenic diets?” *Journal of Child Neurology*, vol. 26, no. 2, pp. 160–165, 2011.

[25] T. Kumada, T. Miyajima, N. Oda, H. Shimomura, K. Saito, and T. Fujii, “Efficacy and tolerability of modified Atkins diet in Japanese children with medication-resistant epilepsy,” *Brain & Development*, vol. 34, no. 1, pp. 32–38, 2012.

[26] S. Sharma, N. Sankhyan, S. Gulati, and A. Agarwala, “Use of the modified Atkins diet in infantile spasms refractory to first-line treatment,” *Seizure*, vol. 21, no. 1, pp. 45–48, 2012.

[27] Y. M. Kim, V. V. Vaidya, T. Khusainov et al., “Various indications for a modified Atkins diet in intractable childhood epilepsy,” *Brain & Development*, vol. 34, pp. 570–575, 2012.

[28] S. Sharma, N. Sankhyan, S. Gulati, and A. Agarwala, “Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial,” *Epilepsia*, vol. 54, pp. 481–486, 2013.

[29] N. E. Payne, J. H. Cross, J. W. Sander, and S. M. Sisodiya, “The ketogenic and related diets in adolescents and adults—a review,” *Epilepsia*, vol. 52, no. 11, pp. 1941–1948, 2011.

[30] E. H. Kossoff, H. Rowley, S. R. Sinha, and E. P. G. Vining, “A prospective study of the modified Atkins diet for intractable epilepsy in adults,” *Epilepsia*, vol. 49, no. 2, pp. 316–319, 2008.

[31] E. Carrette, K. Vonck, V. de Herdt et al., “A pilot trial with modified Atkins’ diet in adult patients with refractory epilepsy,” *Clinical Neurology and Neurosurgery*, vol. 110, no. 8, pp. 797–803, 2008.

[32] E. H. Kossoff, J. L. Borsage, and A. M. Comi, “A pilot study of the modified Atkins diet for Sturge-Weber syndrome,” *Epilepsy Research*, vol. 92, no. 2-3, pp. 240–243, 2010.

[33] M. Smith, N. Politzer, D. MacGarvie, M. P. McAndrews, and M. Del Campo, “Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study,” *Epilepsia*, vol. 52, no. 4, pp. 775–780, 2011.

[34] W. Chen and E. H. Kossoff, “Long-term follow-up of children treated with the modified Atkins diet,” *Journal of Child Neurology*, vol. 27, pp. 754–758, 2012.

[35] E. H. Kossoff, J. L. Dorward, M. R. Molinero, and K. R. Holden, “The modified Atkins diet: a potential treatment for developing countries,” *Epilepsia*, vol. 49, no. 9, pp. 1646–1647, 2008.